Shattuck Labs (STTK) to Release Earnings on Wednesday

Shattuck Labs (NASDAQ:STTK) is expected to be announcing its earnings results on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $1.00 million for the quarter.

Shattuck Labs Stock Performance

STTK stock opened at $1.72 on Tuesday. The company has a market capitalization of $82.11 million, a P/E ratio of -1.12 and a beta of 1.70. Shattuck Labs has a 52-week low of $0.94 and a 52-week high of $11.76. The business has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.83.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on STTK shares. HC Wainwright reiterated a “neutral” rating on shares of Shattuck Labs in a research note on Friday, November 15th. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research note on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Shattuck Labs currently has an average rating of “Hold” and a consensus price target of $8.67.

Insider Transactions at Shattuck Labs

In other Shattuck Labs news, Director Redmile Group, Llc bought 133,371 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average price of $1.25 per share, for a total transaction of $166,713.75. Following the purchase, the director now directly owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. This represents a 2.47 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.50% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.